New hope for transplant patients: drug combo may tame deadly immune attack
NCT ID NCT06936566
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called ruxolitinib for treating acute graft-versus-host disease (GVHD), a serious condition where donor cells attack the patient's body after a bone marrow transplant. About 98 adults with moderate to severe GVHD will receive either ruxolitinib alone or with standard steroids, depending on their risk level. The goal is to see if ruxolitinib can improve response and reduce the need for high-dose steroids, which have harsh side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
-
Fred Hutchinson Cancer Research Center
RECRUITINGSeattle, Washington, 98109, United States
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
Kansas University Medical Center
RECRUITINGFairway, Kansas, 66205, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Moffitt Cancer Center
NOT_YET_RECRUITINGTampa, Florida, 33612, United States
-
Ohio State University
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
-
University of Pennsylvania
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Vanderbilt University
RECRUITINGNashville, Tennessee, 37235, United States
-
Washington University
NOT_YET_RECRUITINGSt Louis, Missouri, 63110, United States
-
Winship Cancer Institute, Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lung protein tame severe graft-versus-host disease?
- Combination drug approach aims to tame immune attack after stem cell transplant
- New shot may shield transplant patients from deadly immune attack
- New drug shows promise in controlling transplant complications
- Poop pills may tame deadly transplant complication
- JAKAVI under the microscope: new study tracks GVHD treatment in real life